Breast cancer claims approximately 670,000 lives each year globally. According to the latest data from the World Health Organization (WHO), breast cancer was the most prevalent cancer among women in 157 out of 185 countries in 2022. More than 2 million women are diagnosed with breast cancer annually. This highlights the importance of early detection and the development of targeted treatments for cancerous cells. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for the treatment of early stage breast cancer when used in combination with hormone therapy. This approval is particularly beneficial for patients concerned about cancer recurrence. The FDA endorsed ribociclib for use with an aromatase inhibitor in the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Kisqali, a selective cyclin-dependent kinase inhibitor, works by targeting proteins CDK4 and CDK6 to slow cancer cell growth and division. It is administered orally in a three-week cycle with one week off, to be continued for three years. The recommended daily oral dose is 400 mg, which can be taken with or without food.Kisqali Ed: Side Effects

Common side effects of Kisqali medication include low white blood cell count or neutropenia. Neutropenia involves reduced levels of neutrophils in the bloodstream, which are crucial for combating infections in the body. Additionally, Kisqali may cause liver-related issues and interstitial lung disease/pneumonitis.

Early Warning Signs of Breast Cancer that Should Not Be Overlooked